



Predictive Factors Of Mortality And Cause's Of Mortality In Systemic Lupus Erythematosus

DR Fathia Ehmouda Zaid ¹ DR Eyans Elmashitai ¹

Fathia Ehmouda Zaid Association Professor -Department of Rheumatology in Faculty of Medicine- Benghazi University Libya

Eyans Elmashitai Department of Rheumatology, in Faculty of Medicine -Benghazi University, Libya

Corresponding author: Fathia Ehmouda Zaid, fatehmoda@yahoo.com -Tel: 0193424950

Abstract ; our study was to assessment morbidity and causes of death in Systemic Lupus erythematosus and assessment prognostic factors predictors of mortality

patient and method Follow up study patients were diagnosed as systemic lupus erythematosus registered at the Rheumatology clinic in between 2009-2020 was performed **Result** Seventy nine patients with diagnosed systemic lupus erythematosus the mean age group affected is 36±8 Years ,female are affected more than male, Most patients have a relapsing and remitting course and continuously active disease, most common morbidity is Hypertension, Recurrent Infection, Diabetes ,Pulmonary hypertension and renal failure& hemodialysis ,the most common mortality is Lupus nephritis followed Infections and prognostic factors influencing survival in our study, Age ,male gender , black race and Sever disease activity ,hypertension, Positive Anti cardiolipin antibody , Renal disease and Neurologic disease **Conclusion** . mortality in patient have SLE during study was (27.8%) The mean age at death in the 33±6 year and most common mortality is disease activity followed Infections

key word ; Systemic lupus erythematosus- morbidity- mortality- disease activity- prognostic factors

Introduction;

Recently new the challenge in Systemic Lupus erythematosus , The five-year survival rate in Systemic Lupus erythematosus (SLE) has dramatically increased since the mid-20th century from approximately 40% in the 1950s to more than 90 %in studies beginning after 1980 (1,2), a trend that has continued into the early 21st century (3) The improvement in patient survival is probably due to multiple factors. These include increased disease recognition with more sensitive diagnostic tests , the advanced medical therapy in and prompt treatment of complications

bimodal pattern of Deaths in patients with SLE were considered as early in patients who died <5 years (from the time of diagnosis of SLE and late in patients who died >5 years after diagnosis(4,5)

The major early Causes of death in SLE is active disease (renal, or cardiovascular disease or cerebrovascular disease) or infection due to immunosuppression, while late deaths are caused by the illness (end-stage renal disease) , by treatment complications (including infection and coronary disease) .(6,7,8)

Race, gender, old age at onset, thrombocytopenia, nephritis, central nervous system involvement , and disease activity are risk factors associated with mortality in patients with SLE(9)

Despite a reduction in the risk of premature death, patients with SLE are at risk for significant morbidity due both to active disease and to the side effects of drugs such as glucocorticoids and cytotoxic agents. (10.11) Glucocorticoid-induced avascular necrosis of the hips and knees, osteoporosis, fatigue, and cognitive dysfunction accumulated organ damage may also be predictive of increased mortality

Patients and method

Follow up study patients were diagnosed as systemic lupus erythematosus registered at the 7th October-Rheumatology clinic in between 2009-2020 was performed

those patients were studied clinically demographics characteristics: age and duration of disease, comorbidities, complete blood count, immunological profile, SLE SLEDAI, SLICC Damage Index score, drug therapy, and cause of mortality

The data analyzed after been collected, to find out the mean, standard deviation and the T test and one way ANOVA using SPSS version 22

Systemic Lupus Erythematosus disease activity index(SLEDAI) have been defined on the basis of SLEDAI scores: no activity (SLEDAI=0), mild activity (SLEDAI=1–5), moderate activity (SLEDAI=6–10), high activity (SLEDAI=11–19), very high activity (SLEDAI>20)

The Systemic Lupus International Collaborating Clinics Damage Index for systemic lupus erythematosus (SLE): damage (nonreversible change) occurring since the onset of lupus, ascertained by clinical assessment and present for at least 6 months. The maximum score is 47 but patients rarely score above 12 points

Ethical

My study done on human body by interviewed with a structured questionnaire in rheumatology clinic, no invasion investigation done and all patients had agreed precipitated in my work

Result

Seventy nine patients with diagnosed systemic lupus erythematosus were included in the study. Patient's demographic and clinical characteristics are shown below

(Table 1). The age of the study patients ranged from (18-55 years), $M=(36\pm 8Y)$ year, 76 (96.2%) were female, the most of the patients were white 69(87.4%) and 10(12.6%) were black, The duration of systemic lupus erythematosus disease range from (3m-20year) $M=10\pm 7y$ According to clinical manifestation of systemic lupus erythematosus we found skin and Mucous membrane are 59(74.7%), arthritis are 68(86.1%), Serositis are 16(20.3%), Hematologic disease 66(83.5%), Renal disease are 37(46.8%), Neurologic disease are 20(25.3%), cardiac disease are 8(10.1%) and Pulmonary manifestation are 16(20.2%)

According to Disease activity patterns was measures Disease Activity Index (SLEDAI) identified 3 main patterns of disease activity relapsing–remitting (RR), chronic active(CA) and long quiescent(LQ), The most common type relapsing–remitting (RR) was 52(65.8%), chronic active(CA) was 19(24.1%) and long quiescent(LQ) was 8 (10.1%). the main systemic lupus erythematosus (SLE) therapies prescribed during the study period are shown below (Table 2) 73 patients (92.4%) received doses of more than 10 mg Prednisolone/day, hydroxychloroquine were prescribed in 50 patients (63.3%), Azathioprine in 45 patients (57%), Pulse cyclophosphamide in 11 patients (14%), mycophenolate Mofetil in 22 patients (27.8%) and rituximab in 18 patients (22.7%). According to long term morbidity of patients In Systemic Lupus Erythematosus was assessment by (SLICC) Systemic Lupus International Collaborating Clinics Damage Index during the study period are shown below (Table 3) we found Alopecia in 12 patient (15.2%), $p = 0.000$, Skin scarring/pigmentation in 14 patients (17.7%), $p = 0.000$, Ischemic heart disease (IHD) in 2 patients (2.5%), $p = 0.159$, Myocarditis in 5 patients (6.3%), $p = 0.045$, Pulmonary hypertension (PAH) in 13 patients (16.5%) $p = 0.000$, End stage renal failure/ hemodialysis in 8 patients (10.1%) $p = 0.000$, Hypertension in 41 patients (51.9%) $p = 0.000$, Neuropsychiatric manifestation in 8 patients (10.1%) $p = 0.001$, Seizures in 5 patients (6.3%), $p = 0.004$, Stroke in 3 patients (3.7%) $p = 0.024$, Diabetes in 10 patients (12.6%) $p = 0.000$, Recurrent Infection in 24 patients (30.3%) $p = 0.000$, Avascular necrosis in 8 patient (7.6%) $p = 0.001$, Osteoporosis in 4 patients (5%) $p = 0.004$ and Oligomenorrhea/amenorrhea in 19 patients (24%) $p = 0.000$,

According to number of death and cause of death of patients In Systemic Lupus Erythematosus are shown below (Table 4) we found number of death during study period 2009- 2020 was 22 patients (27.8%) The mean age at death in the patients in our study was (18years-44years) $M=33\pm 6$, and number of survival of patients was 57(72.2%). The comments' cause of death are caused by active disease manifestations Lupus nephritis/ARF in 9 patients (41%), followed Multiple organ failure in 2 patients (9.1%), alveolar hemorrhage /pneumonitis and Cerebrovascular diseases were one patient (4.6%) and second Infections in 7 patients (32%), followed unknown cause in 2 patients (9.1%), in compared between common cause of death in Systemic Lupus Erythematosus in early five years diagnosis and more five years diagnosis we found renal and infection are common in both with statistical significance. other cause of death are common in early five years diagnosis. According to predicative

factors of mortality in Systemic Lupus Erythematosus during the study period are shown below (Table 5) we found Age < 30 years is $p=0.036$ sex is $p=0.000$, race is $p=0.018$, Sever disease activity (SLEDAI) is $p=0.007$, hypertension is $p=0.002$, Positive Anticardiolipin antibody (AGL) is $P=0.035$, Renal involved is $P=0.001$, central nerve system (CNS) involved is $P=0.052$ all factors with statistical significance

Discussion :

Our studies noted that a large proportion of patients with lupus are white and female the mean age group affected is 36 ± 8 Years, like other studies (2,12)

our analysis noted that a large proportion of patients with lupus are unmarried, reflect wrong ideal about disease in general people of our community.

Most patients have a relapsing and remitting course and continuously active disease (13), most patients 92.4% are received doses of more than 10 mg Prednisolone/day, hydroxychloroquine were 63.3%, Azathioprine were 57%, Pulse cyclophosphamide were 14%, mycophenolate Mofetil were 27.8% and rituximab were 22.7%, morbidity patterns in our patients had Alopecia (15.2%) Skin scarring/pigmentation (17.7%), Ischemic heart disease (IHD) (2.5%), Myocarditis (6.3%), Pulmonary hypertension (PAH) (16.5%), End stage renal failure/ hemodialysis (10.1%), Hypertension (51.9%), Neuropsychiatric manifestation (10.1%), Seizures (6.3%), Stroke (3.7%), Diabetes (12.6%), Recurrent Infection (30.3%), Avascular necrosis (7.6%), Osteoporosis (5%) and Oilgamenorrhoea/amenorrhoea (24%) all statistical significance, reflecting higher disease activity and Medication toxicities, in our findings atherosclerosis and cardiovascular disease not concord with published data (14.15.16) due to the small number and one base hospital center studies.

The most important causes of death in patients with SLE are disease activity (complicated by organ system involvement), treatment related complications such as infections, and long-term disease complications particularly cardiovascular disease (17.18) Despite improvements in immunosuppressive treatment strategies for active disease, infections are still an important cause of death in SLE patients, both early and late in the disease course (17.18.19.20)

Our studies number of death during study period 2009-2020 was (27.8%) The mean age at death in the 33 ± 6 year, and number of survival of patients was (72.2%). The comments' cause of death are caused by active disease manifestations which commonly Lupus nephritis/ARF (41%) and second Infections (32%), followed unknown cause (9.1%), in compared between common cause of death in early five years diagnosis and more five years diagnosis we found renal and infection are common in both with statistical significance. other cause of death are common in early five years diagnosis was near to mortality reported in the most recent studies in which it varied from 6.8% to 20.2% in SLE (3.4.16.17.18)

Among the prognostic factors influencing survival in our study, Age, male gender, black race and Sever disease activity, hypertension Positive Anti cardiolipin antibody (AGL) Renal disease and Neurologic disease. to be affect patient Survival (3.4.18.19.20)

Conclusion

The most common morbidity is Hypertension, Recurrent Infection, Diabetes Pulmonary hypertension, End stage renal failure & hemodialysis, Neuropsychiatric manifestation. and oilgamenorrhoea & amenorrhoea

mortality in patient have SLE during study period was (27.8%).

.The most common mortality is Lupus nephritis followed Infections followed unknown cause renal and infection are common cause of death are in early five years diagnosis and more five years diagnosis of systemic lupus erythematosus

The prognostic factors influencing survival of disease are Age, male gender, black, Sever disease activity, hypertension, Positive Anti cardiolipin antibody (AGL) Renal disease and Neurologic disease

Recommendations;

Education, insertion new trend management and early diagnostic with good follow up are improve mortality in patient with Systemic Lupus Erythematosus

Limitation of study

small number and due to the large amount of missing data and one base clinical hospital lack date for evaluation risk cardiovascular disease which important cause mortality in systemic lupus erythematosus

Conflicts of interest

had no conflicts of interest

Acknowledgment

Grateful to all patients who participated and help in accomplishing

References

- 1-Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. *Curr Opin Rheumatol* 2001; 13:345
- 2-Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine (Baltimore)* 2003; 82:299
- 3-Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. *Medicine (Baltimore)* 2006; 85:147.
- 4-Urowitz MB, Gladman DD, Tom BD, et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. *J Rheumatol* 2008; 35:2152.
- 5-Callahan LF, Pincus T. Mortality in the rheumatic diseases. *Arthritis Care Res* 1995; 8:229.
- 6-Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. *European Working Party on Systemic Lupus Erythematosus. Medicine* 1999; 78: 167–175
- 7-Tselios, K.; Gladman, D.D.; Su, J.; Ace, O.; Urowitz, M.B. Evolution of risk factors for atherosclerotic cardiovascular events in systemic lupus erythematosus: A longterm prospective study. *J. Rheumatol.* 2017, 44, 1841–1849
- 8- Kedves, M.; Kosa, F.; Kunovszki, P.; Takacs, P.; Szabo, M.Z.; Karyekar, C.; Lofland, J.H.; Nagy, G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. *Rheumatology* 2020,59, 3443–3451
- 9-Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. *Arch Intern Med* 1996; 156:1337.
- 10-Rees, F.; Doherty, M.; Grainge, M.; Lanyon, P.; Davenport, G.; Zhang, W. Burden of comorbidity in systemic lupus erythematosus in the UK, 1999–2012. *Arthritis Care Res.* 2016, 68, 819–827
- 11-Stoll T, Sutcliffe N, Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study. *Rheumatology (Oxford)* 2004; 43:1039
- 12-Houman MH, Smiti-Khanfir M, Ben Ghorbell I, Miled M. Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients. *Lupus* 2004; 13: 204–211.
- 13-Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. *Arthritis Rheum* 1999;42:1785-96

14-Rivest C, Lew RA, Welsing PM, Sangha O, Wright EA, Roberts WN, et al. Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. *J Rheumatol* 2000;27:680-4

15-Gladman DD, Urowitz MB. Prognosis, mortality and morbidity in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. *Dubois' Lupus Erythematosus*. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2002:1255-1273

16-Parker, B.; Urowitz, M.B.; Gladman, D.D.; Lunt, M.; Bae, S.C.; Sanchez-Guerrero, J.; Romero-Diaz, J.; Gordon, C.;Wallace, D.J.Clarke, A.E.; et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort. *Ann. Rheum. Dis.* 2013, 72, .1308–1314

17-Alamanos Y, Voulgari PV, Parassava M, et al. Survival and mortality rates of systemic lupus erythematosus patients in northwest Greece. Studyof a 21 years incidence cohort. *Rheumatology*. 2003;42:1122-1123

18-Abu-Shakra M, Urowitz MB, Gladman DD, GoughJ. Mortality studies in systemic lupus Results from a single centre. I. Causes of death. *J Rheumatol* 1995;22:1259–64

19-Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. *Ann Rheum Dis.* 2002;61:409-413

20-Bellomio V, Spindler A, Lucero E, et al. Systemic lupus erythematosus: mortality and survival in Argentina. A multicenter study. *Lupus*. 2000; 9:377-381



Table [1] demographic and Clinical Characteristics of patients In Systemic Lupus Erythematosus

Age	18-55years M=(36±8Y)
sex	76 female(96.2%) 3 male (3.8%)
Race; White Black	69(87.4%) 10(12.6%)
Marital state	18(22.7%)
Duration disease	3m-20year M =[10±7y]
skin manifestation	59(74.7%)
Arthritis	68(86.1%)
Serositis	16(20.3%)
Hematologic manifestation	66(83.5%)
Renal manifestation	37(46.8%)
Neurologic manifestation	20(25.3%)
Cardiac manifestation	8(10.1%)
Pulmonary manifestation	16(20.2%)
patterns of SLE activity relapsing–remitting(RR) chronic active(CA) long quiescent (LQ)	52(65.8%) 19(24.1%) 8 (10.1%)

Table[2] Drug therapy in patients with Systemic Lupus Erythematosus

Steroid	73 (92.4%)
Antimalarial(hydroxychloroquine)	50 (63.3%)
Azathioprine	45(57%)
Pulse cyclophosphamide	11(14%)
mycophenolate Mofetil	22(27.8%)
rituximab	18(22.7%)

Alopecia	12(15.2%)	0.000
Skin scarring/pigmentation	14(17.7%)	0.000
Ischemic heart disease(IHD)	2(2.5%)	.159
Myocarditis	5(6.3%)	0.045
Pulmonary hypertension(PAH)	13(16.5%)	0.000
End stage renal failure/hemodialysis	8(10.1%)	0.000
Hypertension	41(51.9%)	0.000
Neuropsychiatric manifestation	8(10.1%)	0.001
Seizures	5(6.3%)	0.004
Stroke	3(3.7%)	0.024
Diabetes	10 (12.6%)	0.000
Recurrent Infection	24(30.3%)	0.000
Avascular necrosis	6(7.6%)	0.001
Osteoporosis	4(5%)	0.004
Oilgamenorrhea/amenorrhea	19(24%)	0.000

SLICC Systemic Lupus International Collaborating Clinics Damage Index score, T test, $p \leq 0.05$

No. of death	22(27.8%)		
No. of survival	57(72.2%)		
Cause of death		Early death <5 years after diagnosis of SLE	Late death >5 years after diagnosis of SLE
A- caused by active disease manifestations			
Multiple organ failure	2 (9.1%)	.014	.249
Lupus nephritis/ARF	9 (41%)	.000	.032
alveolar hemorrhage/pneumonitis	1(4.6%)	.001	.588
Cerebrovascular diseases	1(4.6%)	.001	.588
B-Infections	7(32%)	.004	.000
C-Unknown	2(9.1%)	.014	.249

Age	.036
Sex(male)	.000
Race(black)	.018
Duration disease	.306
Sever disease activity (SLEDAI)	.007
hypertension	.002
Positive Anticardiolipin antibody(AGL)	.035
Renal involved	.001
CNS involved	.052